UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN)

Q: What does CUSIP M96088105 represent in this 13F holders report?

CUSIP M96088105 is the security identifier for URGN - UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share used to aggregate holder disclosures.

Q: How many institutions held URGN - UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share in Q2 2017?

21 institutional investors reported URGN - UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share for Q2 2017. Use the holders table for investor-level position and value details.

CUSIP: M96088105

Q2 2017 13F Holders as of 30 Jun 2017

Type / Class: Equity / Ordinary Shares, par value NIS 0.01 per share
Shares outstanding: 46,986,408
Total 13F shares: 4,717,310
Share change: +4,717,310
Total reported value: $85,197,000
Price per share: $18.06
Number of holders: 21
Value change: +$85,197,000
Number of buys: 21

Quarterly Holders Quick Answers

What is CUSIP M96088105?
CUSIP M96088105 identifies URGN - UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2017

Recent filing periods for CUSIP M96088105:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of URGN - UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

No top shareholder records were found across 13F, 13D/G, and Forms 3/4/5 for this issuer.

Institutional Holders of UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) as of Q2 2017

As of 30 Jun 2017, UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) was held by 21 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 4,717,310 shares. The largest 10 holders included ProQuest Associates IV LLC, FMR LLC, WELLINGTON MANAGEMENT GROUP LLP, HIGHLINE CAPITAL MANAGEMENT, L.P., Hillhouse Capital Management, Ltd., PERCEPTIVE ADVISORS LLC, JENNISON ASSOCIATES LLC, Wildcat Capital Management, LLC, MENORA MIVTACHIM HOLDINGS LTD., and Alyeska Investment Group, L.P.. This page lists 21 institutional shareholders reporting positions in this security for the Q2 2017 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2017 vs Q4 2025 Across Filers

Q4 2025 holders

166

Q2 2017 holders

Holder diff

-145

Investor	Q4 2025 Shares	Q2 2017 Shares	Share Diff	Share Chg %	Q4 2025 Value $	Q2 2017 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.